Knight Receives Adverse Notice of Reassessment from CRA

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
75
Knight Receives Adverse Notice of Reassessment from CRA

MONTREAL, July 06, 2018 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD ) (“Knight”), a leading Canadian specialty pharmaceutical company, announced today that it has received a notice of reassessment (“CRA Notice”) from the Canada Revenue Agency (“CRA”) for its fiscal year ended December 31, 2014.

The CRA Notice relates to the disposition of the Priority Review Voucher ("PRV") granted on March 19, 2014, upon the US Food & Drug Administration’s (“FDA”) approval of Impavido®.  The PRV was disposed of by Knight’s wholly-owned subsidiary, Knight Therapeutics (Barbados) Inc. (“KTB”), to a third party in November 2014 for gross proceeds of US$125 million. The proceeds have contributed to the development of the business operations of KTB, including the out-licensing of Impavido®, as well as business development strategies designed to acquire additional pharmaceutical product rights. The CRA Notice provides that Knight is liable to pay to the CRA an aggregate of $23.3 million in additional taxes and interest. It is likely that the Quebec Revenue Agency (“QRA”) will propose a similar adjustment which will result in an estimated additional tax liability of $19.0 million increasing the total additional taxes, interest and penalties to $42.3 million (“Total Tax Liability”).

Knight believes that the CRA Notice is unfounded and intends to contest vigorously the CRA Notice by filing a notice of objection to start the appeals process. However, there can be no assurance regarding the outcome of the appeals process or when a resolution may be reached. In connection with the appeals process, Knight has made a deposit of $23.3 million to the CRA and will make an estimated deposit of $19.0 million to QRA. Knight has not recorded any tax provision for the Total Tax Liability in its financial statements. Although Knight believes its tax provisions are adequate, the final determination of tax audits and any related disputes could be materially different from historical income tax provisions and accruals. 

About the FDA PRV Program

A Priority Review Voucher is a transferrable asset that entitles the holder to a priority review for a drug of its choice. A priority review means that the review time of the FDA for a new drug application is reduced by approximately six months. The PRV program was designed to incentivize the development of treatments for diseases that might otherwise not attract development interest due to the cost and the lack of market opportunities.

About Knight Therapeutics Inc. 

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian and select international markets. Knight Therapeutics Inc.'s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at www.gudknight.com or www.sedar.com. 

Forward-Looking Statement

This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2017. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events, except as required by law. 

CONTACT INFORMATION:

Knight Therapeutics Inc. Samira Sakhia President & Chief Financial Officer T: 514-678-8930 F: 514-481-4116 info@gudknight.com www.gudknight.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Daqo New Energy Faces Key Investor Meeting in December

Updated Category News Views 88

Spotlight on December's Agenda for Daqo Shareholders Who'd have thought we'd be looking at another year end with the same burning energy interests? Daqo New Energy Corp. (NYSE: DQ) is setting up for its annual general meeting (AGM) dated December 10, 2026. Mark your calendars, because these gatherings can be more than just straightforward affairs; sometimes they reveal...

Continue Reading
Bacterial Breakthrough in Cancer Therapy: Game Changer?

Updated Category News Views 7

Blurring Lines Between Bugs and Biotech Well, wouldn't you know it, the eggheads over at Jeonbuk National University in South Korea are at it again, pushing the boundaries of what these little bacterial buggers can do. This time, they’ve had a crack at cancer therapy, using engineered Salmonella to pack a double punch against breast cancer in mice. Now, if that ain't...

Continue Reading
IQSTEL's Nine-Month Revenue Hits $313M, Growth Impresses

Updated Category News Views 41

Pushing Through With Persistence Well, well, well, here we are, talking about IQSTEL Inc. (NASDAQ: IQST) slinging some serious numbers—not the kind you can ignore at your breakfast table. The company pulled in a whopping $313 million in revenue over the first nine months of 2026. That’s a bump up by 34.5% from last year’s $232.7 million. What’s behind the magic...

Continue Reading
AdMaven's Mave AI: Revolutionizing Campaign Management

Updated Category News Views 19

Taking the Tedious Out of Advertising You've got to love it when technology actually makes life easier, rather than more complicated. AdMaven's latest fancy toy, the AI assistant Mave, is promising just that. It's designed to take the heavy lifting off advertisers' shoulders, especially the day-to-day grind of tweaking ad settings and monitoring performance. If you've...

Continue Reading
Dawson Struggles With Q3 Losses Despite Growth Prospects

Updated Category News Views 42

Profit and loss dance around like a jittery stock, and Dawson Geophysical is feeling the heat this third quarter. Numbers are in, and we’re seeing a net loss of $5.2 million, translating to $0.17 per share—ouch. Not to mention a negative Adjusted EBITDA of $2 million. Compared to last year's hopes, that's a serious belly flop. Revenue Down, Hopes Up In a fetching...

Continue Reading
DoGo Power Revamps Energy for Remote Indonesian Isle

Updated Category News Views 114

Bringing Light to Pagerungan Kecil Island These days, if you wander into the fishing communities of Pagerungan Kecil Island, the buzz isn't just from the daily catch. Residents are talking about power, and not the kind you get from a generator spluttering along—I'm talking about a brand-new energy storage system that’s turning the lights on in ways these folks have...

Continue Reading
Roche Delivers Endotrophin Assay to Nordic Bioscience Lab

Updated Category News Views 52

Roche Opens New Frontier in Diagnostic Biomarkers Get ready to chew on this: Roche Diagnostics is bringing something new to Nordic Bioscience's CLIA lab. They're offering up their Endotrophin research prototype assay on the cobas® e801 Analyzer. Now, what does this mean for the scientific world? Well, it might just shake things up for those battling cardiovascular and...

Continue Reading
DarioHealth's New Research Tackles Healthcare Cost Estimation

Updated Category News Views 91

Unpacking Dario's Bold Surgical Strike at ISPOR Europe Alright, folks, DarioHealth is shaking up the stage with their new methodology that could very well carve a new path in how we size up digital healthcare savings. Presented at ISPOR Europe 2026, Dario's tactic bypasses the sluggish wait on medical claims data, instead offering an evidence-driven peek at potential...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 147

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
ICCSD in Beijing: AI and Culture's Future Explored

Updated Category News Views 136

AI's Intersection with Culture in the Spotlight Imagine a room full of people hammering out the future of AI and culture—it starts to feel like a melting pot for the mind. That was the scene in Beijing when the ICCSD Advisory Committee congregated on October 26, 2026. With experts pooling from four different countries, there was no shortage of fireworks. They hashed out...

Continue Reading

Top 5 Most Recently Viewed Articles

Moatable, Inc. Concludes the Tender Offer for Class A Shares

Updated Category News Views 139

Moatable, Inc. Completes Tender Offer for Class A Shares Moatable, Inc. (Pink Limited Market: MTBLY), a premier US-based SaaS company, has announced the successful completion of its fixed price tender offer. The company aimed to repurchase an impressive 225 million Class A ordinary shares. Each share has a par value of $0.001, and they can also be represented by American...

Continue Reading
Armstrong World Industries' Q4 Earnings: What Investors Need

Updated Category News Views 164

Armstrong World Industries Q4 Earnings Report Let’s dive right into this latest earnings report from Armstrong World Indus (NYSE:AWI) that just hit the streets. Released on February 24, 2026, bright and early, it’s got both good news and some not-so-great tidbits that every investor should chew on. Honestly, missing earnings estimates by a margin like -3.59% just...

Continue Reading
Batteries Plus Enhances Partnership for Educational Safety Needs

Updated Category News Views 254

Batteries Plus Enhances Partnership for Educational Safety Needs From Campus Fleets to Classroom Security, Local Teams Support Operational Readiness for Schools and Universities Nationwide Batteries Plus is deepening its partnerships with K-12 districts, colleges, and universities by supplying a broad range of comprehensive battery, lighting, and security system support....

Continue Reading
Exciting Developments in Houston: The RO Project Advances

Updated Category News Views 453

Transwestern Launches Next Phase of The RO Development Transwestern, a prominent commercial real estate firm headquartered in Houston, has taken a monumental step forward by breaking ground on the next phase of The RO. This innovative project aims to redefine the River Oaks neighborhood, representing a significant addition to the area that harmonizes various aspects of...

Continue Reading
BMO Financial Group Plans Large Share Repurchase Initiative

Updated Category News Views 95

BMO Financial Group's Strategic Share Buyback Program Bank of Montreal (TSX:BMO)(NYSE:BMO) has announced an ambitious plan to repurchase up to 20 million common shares through a normal course issuer bid. This initiative is designed to strengthen the bank's capital structure and reflects its confidence in its business fundamentals. Details of the Share Repurchase Plan The...

Continue Reading